在精神分裂症中针对多种机制的辅助治疗的理由
Bruce J Kinon1,2, Stefan Leucht3, Carol Tamminga4
1Karuna Therapeutics, Boston, Massachusetts.
The Journal of clinical psychiatry
|August 28, 2024
概括
对于精神分裂症,需要针对非多巴胺途径的新型抗精神病治疗. 新型药物可能会改善治疗耐药性或当前多巴胺D2受体阻断剂副作用的患者的治疗结果.
科学领域:
- 神经科学是一个神经科学.
- 精神病学是一个精神病学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 精神分裂症的治疗仍然具有挑战性,目前的多巴胺D2受体对抗剂具有局限性.
- 现有的抗精神病药物通常对负面症状和认知缺陷无效,并引起副作用.
- 精神分裂症的病理生理学涉及多种神经递质系统,除了多巴胺.
研究的目的:
- 突出对综合性精神分裂症症状管理的未满足需求.
- 探索超越多巴胺D2受体对抗性的新疗法.
主要方法:
- 审查目前的精神分裂症治疗限制.
- 分析关于精神分裂症非多巴胺基通路的新兴证据.
主要成果:
- 目前的抗精神病药主要针对积极症状,并具有显著的副作用.
- 精神分裂症的负面症状和认知障碍没有得到充分的解决.
- 谷氨酸,乙胆,血清素和GABA系统的功能障碍与此有关.
结论:
- 迫切需要治疗解决所有核心精神分裂症症状的治疗方法.
- 非多巴胺类抗精神病药物显示出作为辅助疗法的前景.
- 新型药物可能有利于治疗耐药性或对当前药物的耐受性差的患者.
相关概念视频
Drug Therapy
40
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
40
Alzheimer's Disease: Treatment
170
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
170
Psychosis: Goals of Pharmacotherapy
113
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
113
Antidepressant Drugs: MAOIs and Other Agents
205
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
205
Psychosis and Antipsychotic Drugs: Overview
203
The term "psychosis" refers to a spectrum of mental disorders characterized by abnormal thoughts, perceptions, and behaviors. It can manifest as mood disorders, dementia, delirium with psychotic features, substance-induced psychosis with psychotic features, brief psychotic disorder, delusional disorder, schizoaffective disorder, and schizophrenia. Among all these disorders, schizophrenia is the most common psychotic disorder, affecting 1% of the worldwide population. Psychotic...
203
Parkinson's Disease: Treatment
239
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
239


